INS and metabolic syndrome: The observed clinical effect is attributed to the modulation of insulin signaling pathways as a result of improvement of proliferative activity and viability of ASCs affected by metabolic syndrome, as a result of their reduced senescence manifested by β-galactosidase activity, and as a result of reduced ASC apoptosis inducers involved in regulating cellular senescence progress and proliferation.